 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Companys common stock at an exercise price per share of 30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company 